<DOC>
	<DOCNO>NCT01431196</DOCNO>
	<brief_summary>Molecular expression breast cancer ( BC ) define special fenotypes different prognostic predictive features.Since addition trastuzumab lapatinib chemotherapy , HER2 overexpressing tumor become best responder systemic therapy , reach pathologic complete response rate ( pCR ) around 50 % . But HER2 negative tumor ( luminal A triple negative ) characterize low chemosensitivity ( luminal A ) early distant relapse diagnosis ( triple negative BC ) . In open , prospective , non-randomized multicentric phase II study investigator include stage II III HER2 negative BC patient go receive neoadjuvant sequential chemotherapy Epirubicin+Ciclofosfamide x 4 Docetaxel x 4 ) individualize vaccination autologous dendritic cell pulse tumor . The hypothesis reinforcement immune system autologous dendritic cell vaccination HER2 negative BC could increase pathologic complete response ( pCR ) disease free survival ( DFS ) , add chemo , surgery radiation therapy maintenance schedule .</brief_summary>
	<brief_title>Trial With Autologous Dendritic Cell Vaccination Patients With Stage II-III HER2 Negative Breast Cancer</brief_title>
	<detailed_description>Chemotherapy schedule : - dose dense epirubucin 100 mgr/m2 plus ciclofosfamide 600 mgr/m2 every two week four cycle GM-CSF support day +1 ( pegylated filgastrim ) day +5 +9 ( filgastrim ) subcutaneously - docetaxel 80-100 mgr/m2 every three week four cycle . Addition GM-CSF docetaxel dose &gt; 85 mgr/m2</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>HER2 negative stage II III Breast cancer patient benefit neoadjuvant chemotherapy age 1875 get enough tumoral sample elaborate vaccine pregnancy severe diseases hepatitis HIV need immunosuppressant drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>autologous dendritic cell vaccination</keyword>
</DOC>